Discovery of benzimidazo-2-amino-1,3,4-thiadiazole carboxylate small-molecule STAT3 inhibitors for colorectal carcinoma therapy

Puntos clave

• Inhibitors effectively reduce tumor growth in colorectal carcinoma, with significant preclinical results.
• The most potent benzimidazo-2-amino-1,3,4-thiadiazole compound showed a 75% decrease in tumor volume.
• Through observational analysis and in vitro studies, the focus is on small-molecule interactions with STAT3.
• These findings highlight the potential for targeted therapy in colorectal cancer using novel compounds.